Literature DB >> 30559071

AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity.

Defne A Amado1, Julianne M Rieders2, Fortunay Diatta1, Pilar Hernandez-Con1, Adina Singer1, Jordan T Mak1, Junxian Zhang1, Eric Lancaster1, Beverly L Davidson3, Alice S Chen-Plotkin4.   

Abstract

Adeno-associated virus-mediated gene replacement is emerging as a safe and effective means of correcting single-gene mutations affecting the CNS. AAV-mediated progranulin gene (GRN) delivery has been proposed as a treatment for GRN-deficient frontotemporal dementia and neuronal ceroid lipofuscinosis, and recent studies using intraparenchymal AAV-Grn delivery to brain have shown moderate success in histopathologic and behavioral rescue in mouse models. Here, we used AAV9 to deliver GRN to the lateral ventricle to achieve widespread expression in the Grn null mouse brain. We found that, despite a global increase in progranulin, overexpression resulted in dramatic and selective hippocampal toxicity and degeneration affecting neurons and glia. Hippocampal degeneration was preceded by T cell infiltration and perivascular cuffing. GRN delivery with an ependymal-targeting AAV for selective secretion of progranulin into the cerebrospinal fluid similarly resulted in T cell infiltration, as well as ependymal hypertrophy. Interestingly, overexpression of GRN in wild-type animals also provoked T cell infiltration. These results call into question the safety of GRN overexpression in the CNS, with evidence for both a region-selective immune response and cellular proliferative response. Our results highlight the importance of careful consideration of target gene biology and cellular response to overexpression prior to progressing to the clinic.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV; CNS gene therapy; brain gene therapy; frontotemporal dementia; neurodegeneration; neuronal ceroid lipofuscinosis; progranulin

Mesh:

Substances:

Year:  2018        PMID: 30559071      PMCID: PMC6369714          DOI: 10.1016/j.ymthe.2018.11.013

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  55 in total

1.  Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice.

Authors:  Hans Wils; Gernot Kleinberger; Sandra Pereson; Jonathan Janssens; Anja Capell; Debby Van Dam; Ivy Cuijt; Geert Joris; Peter P De Deyn; Christian Haass; Christine Van Broeckhoven; Samir Kumar-Singh
Journal:  J Pathol       Date:  2012-06-25       Impact factor: 7.996

Review 2.  Frontotemporal dementia: a review.

Authors:  Murray Grossman
Journal:  J Int Neuropsychol Soc       Date:  2002-05       Impact factor: 2.892

3.  Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.

Authors:  Eloise Hudry; Jonathan Dashkoff; Alysson D Roe; Shuko Takeda; Robert M Koffie; Tadafumi Hashimoto; Maria Scheel; Tara Spires-Jones; Michal Arbel-Ornath; Rebecca Betensky; Beverly L Davidson; Bradley T Hyman
Journal:  Sci Transl Med       Date:  2013-11-20       Impact factor: 17.956

4.  Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy.

Authors:  Yi Gong; Dakai Mu; Shilpa Prabhakar; Ann Moser; Patricia Musolino; JiaQian Ren; Xandra O Breakefield; Casey A Maguire; Florian S Eichler
Journal:  Mol Ther       Date:  2015-01-16       Impact factor: 11.454

5.  Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors.

Authors:  Gumei Liu; Inês Martins; John A Wemmie; John A Chiorini; Beverly L Davidson
Journal:  J Neurosci       Date:  2005-10-12       Impact factor: 6.167

6.  Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration.

Authors:  Alice S Chen-Plotkin; Maria Martinez-Lage; Patrick M A Sleiman; William Hu; Robert Greene; Elisabeth McCarty Wood; Shaoxu Bing; Murray Grossman; Gerard D Schellenberg; Kimmo J Hatanpaa; Myron F Weiner; Charles L White; William S Brooks; Glenda M Halliday; Jillian J Kril; Marla Gearing; Thomas G Beach; Neill R Graff-Radford; Dennis W Dickson; Rosa Rademakers; Bradley F Boeve; Stuart M Pickering-Brown; Julie Snowden; John C van Swieten; Peter Heutink; Harro Seelaar; Jill R Murrell; Bernardino Ghetti; Salvatore Spina; Jordan Grafman; Jeffrey A Kaye; Randall L Woltjer; Marsel Mesulam; Eileen Bigio; Albert Lladó; Bruce L Miller; Ainhoa Alzualde; Fermin Moreno; Jonathan D Rohrer; Ian R A Mackenzie; Howard H Feldman; Ronald L Hamilton; Marc Cruts; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Thomas D Bird; Nigel J Cairns; Allison Goate; Matthew P Frosch; Peter F Riederer; Nenad Bogdanovic; Virginia M Y Lee; John Q Trojanowski; Vivianna M Van Deerlin
Journal:  Arch Neurol       Date:  2011-04

Review 7.  Astrocytes: biology and pathology.

Authors:  Michael V Sofroniew; Harry V Vinters
Journal:  Acta Neuropathol       Date:  2009-12-10       Impact factor: 17.088

8.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

9.  Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models.

Authors:  Arnaud Tauffenberger; Babykumari P Chitramuthu; Andrew Bateman; Hugh P J Bennett; J Alex Parker
Journal:  Hum Mol Genet       Date:  2012-11-19       Impact factor: 6.150

Review 10.  Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.

Authors:  Céline Vandamme; Oumeya Adjali; Federico Mingozzi
Journal:  Hum Gene Ther       Date:  2017-11       Impact factor: 5.695

View more
  18 in total

Review 1.  Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.

Authors:  Yazhou Cui; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2019-01-30       Impact factor: 7.638

Review 2.  Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary.

Authors:  Jill A Morris; Chris H Boshoff; Nina F Schor; Ling M Wong; Guangping Gao; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-09-20       Impact factor: 11.454

3.  Thioredoxin-Interacting Protein (TXNIP) Knockdown Protects against Sepsis-Induced Brain Injury and Cognitive Decline in Mice by Suppressing Oxidative Stress and Neuroinflammation.

Authors:  Yu Zhang; Cheng-Jun Xing; Xiao Liu; Ya-Hong Li; Jing Jia; Jian-Guo Feng; Cheng-Jie Yang; Ye Chen; Jun Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-05-05       Impact factor: 7.310

4.  A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity.

Authors:  Winston Colon-Moran; Alan Baer; Gauri Lamture; Jack T Stapleton; Joseph W Fischer; Nirjal Bhattarai
Journal:  Gene Ther       Date:  2021-11-11       Impact factor: 4.184

Review 5.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

6.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

Review 7.  Battling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches.

Authors:  Olja Mijanović; Ana Branković; Anton Borovjagin; Denis V Butnaru; Evgeny A Bezrukov; Roman B Sukhanov; Anastasia Shpichka; Peter Timashev; Ilya Ulasov
Journal:  Viruses       Date:  2020-04-18       Impact factor: 5.048

Review 8.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 9.  Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease.

Authors:  Sophia R L Vieira; Huw R Morris
Journal:  Front Neurol       Date:  2021-06-04       Impact factor: 4.003

10.  Discovery of small molecules that normalize the transcriptome and enhance cysteine cathepsin activity in progranulin-deficient microglia.

Authors:  Maria A Telpoukhovskaia; Kai Liu; Faten A Sayed; Jon Iker Etchegaray; Min Xie; Lihong Zhan; Yaqiao Li; Yungui Zhou; David Le; Ben A Bahr; Matthew Bogyo; Sheng Ding; Li Gan
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.